TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in NK cells frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Treg and Th17 cells frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in secretion levels of cytokines (IL-17, IL-21, TGF-B, IL-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients discharged alive
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Major Vascular Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Daily frequency of blood glucose monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients without documented tumor progression at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change in Modified Rodnan Skin Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma elongated n-3 PUFA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of myocardial injury after non cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Diurnal IOP Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Plasma concentrations of AZD9668
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of Nelfinavir treatment on Kaposi Sarcoma lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under The Concentration Versus Time Curve (AUC0-inf) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Maximum Observed Concentration (Tmax) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dispensing of Psychotropic Medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Behavioral Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rejection of Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment emergent adverse events (AEs) and serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intima media thickness of carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cerebrovascular accident
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: renal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Unnecessary Loop Electrosurgical Excision Procedures (LEEP)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum-tolerated dose (MTD) of bortezomib in combination with decitabine
Endpoint domain: Adverse events/effects
Primary endpoint: Specific toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: DLT of bortezomib in combination with decitabine
Endpoint domain: Adverse events/effects
Primary endpoint: Antithrombin III levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum seriousness grade of acute pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adherence to Oral Chemotherapy Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of rescue medication needed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: proportion of children with antibody concentration ≥0.35µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Synaptic Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of good quality cleavage embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embryo utilization rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Anti-HA individual titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Individual titers ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion or significant increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of modified Rankin Scale (mRS) 0-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine urine toxicology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with grade 3 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Continuing Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients That Achieve Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of volunteers with treatment-emerged adverse events of any grade
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of volunteers with treatment-emerged adverse events of grade 3 and higher
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of volunteers with both binding and neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants who Experience Adverse Events Within 28 days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants who Experience Reactogenicity Symptoms Following Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Evoked Bladder Contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean Change of Motor Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of high-grade anal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of anal HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quantification of spontaneous regression of high-grade anal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: invasive disease free survival
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants meeting diagnostic criteria for metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lumbar Spine Surgery Expectations Survey scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stricture Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Static Photographic Physician Global Assessment (PGA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Photographic Physician Global Assessment (PGA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour urinary LH excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oxidative stress measured by TBARS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function changes - attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive function changes - inhibitory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hemoglobin before delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive Test Performance: Spatial Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Test Performance: Virtual Navigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of Prescription Sleep Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Efficacy of vemurafenib in combination with obinutuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: THV dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantification of uterine bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial gingival level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality for detection of cervical dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Systolic Blood Pressure at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Fasting Blood Glucose at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in left ventricular filling pressures during volume loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anxiety Disorder Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of erectile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Smoking Intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of early recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Experienced a Treatment-emergent Anaphylactic Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of S.pneumoniae serotypes included in PCV13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of procedure related SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: CSF flow measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC of Vilaprisan in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Vilaprisan in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newly onset ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular events including newly onset TIA, intracerebral hemorrhage, myocardial infarction, unstable angina pectoris, occlusion of peripheral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Small vessel disease defined by white matter lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ad libitum snack intake (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ad libitum pizza intake (kcal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myocardial Tissue Characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Functional Characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Scaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evaluation of teeth restored
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS-score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change of Heart Rate Variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cartilage signal quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Requiring Rescue Intravenous Opioid
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical phenotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of reinjections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ageism
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of subjects reaching an ED ≥1000 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and toxicity of FUSA
Endpoint domain: Adverse events/effects
Primary endpoint: Increased CD8+ T cell infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hearing Aid Performance Benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Experience One or More Wound Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Children Responding to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspirated secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of cancerous nodules with tumor stage greater than T1a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to First Occurrence of Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Observed Participants With Outcome Measure Events During the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody retention rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite Learning and Memory Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of complete abortions without surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exclusive breastfeeding (EBF) among children 0-6 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Desaturation Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 24-hour BP (Systolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour BP (Diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: non-operative mortality within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: time from ICU admission to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total inotrope score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression of Ki67 on tumor samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: myocardium infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intratumoral and plasma pharmacokinetics of AC480
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-syn levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-syn levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-syn levels in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-syn deposits in skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-syn deposits in submandibular gland
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-syn deposits in colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Episodic Memory Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change in Neural Modulation Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Surface Area of Abscess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IP Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function as measured by the Montreal Cognitive Assessment (MoCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in EASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear Accelerator time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pulmonary Bioavailability After Inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Iron status in preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with autoimmune cytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SF-36 Physical Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EQ-5D Self Reported Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Operative mesh related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Concordance of T790M mutation testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Self-Test Fingerstick Blood Glucose Results within +/- 15mg/dL or +/- 15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fluctuations of 2-AG plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Sino-Nasal Outcome Test (SNOT)-22 Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Intraocular Pressure at 9:00 am
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Intraocular Pressure at 11:00 am
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Intraocular Pressure at 4:00 pm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of mayo criteria in UC patients after FMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse events after FMT
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tear protein composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral TBE Immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to diagnosis of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding from gastric varix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain of needle penetration during buccal LA injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain of anesthesia delivery during buccal LA infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain of needle penetration during palatal LA injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain of anesthesia delivery during palatal LA infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain of needle penetration during IAN block LA injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain of anesthesia delivery during IAN block LA injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of ASP0456
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in side effects of pain medication
Endpoint domain: Adverse events/effects
Primary endpoint: Facial Volume Appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal healing status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: inhalation technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Inspiratory muscles strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in agoraphobic situation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of patients free of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting toxicity for the AG-mFOLFOX combination
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of overall survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Positivity for NTCVAG04 in rectal swabs
Endpoint domain: Adverse events/effects